Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Study on Pulmonary Rehabilitation for Stable Chronic Obstructive Pulmonary Disease(COPD) Patients

Not Applicable

Conditions: Muscle Strength
Respiratory Function Tests
Nutritional Support
Aerobic Exercise
Body Composition

Interventions: Behavioral: rehabilitation exercise
Dietary Supplement: oral nutritional supplements
Other: health education

First Posted Date: 2021-02-05

Last Posted Date: 2021-04-13

Lead Sponsor: Fudan University

Target Recruit Count: 90

Registration Number: NCT04741373

Locations: 🇨🇳
Huadong Hospital Affiliated to Fudan University, Shanghai, China

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Sitravatinib
Drug: Tislelizumab
Drug: Nab-paclitaxel

First Posted Date: 2021-02-02

Last Posted Date: 2023-11-18

Lead Sponsor: Fudan University

Target Recruit Count: 98

Registration Number: NCT04734262

Locations: 🇨🇳
Fudan University Shanghai Cancer, Shanghai, Shanghai, China

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Phase 1

Active, not recruiting

Conditions: Urinary Bladder Neoplasms
Immunotherapy

Interventions: Drug: Camrelizumab

First Posted Date: 2021-01-13

Last Posted Date: 2024-07-12

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT04706598

Locations: 🇨🇳
Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Shanghai Tenth People's Hospital,Shanghai Tong Ji University School of Medicine, Shanghai, Shanghai, China

and more 1 locations

Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

Phase 2

Conditions: Lung Cancer, Non-small Cell

Interventions: Drug: Pyrotinib combined with pemetrexed plus carboplatin

First Posted Date: 2021-01-13

Last Posted Date: 2021-01-13

Lead Sponsor: Fudan University

Target Recruit Count: 26

Registration Number: NCT04706949

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy

Phase 1

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: Nab-paclitaxel+GEM
Drug: cisplatin+Nab-paclitaxel+GEM

First Posted Date: 2021-01-13

Last Posted Date: 2021-01-13

Lead Sponsor: Fudan University

Target Recruit Count: 106

Registration Number: NCT04707118

Locations: 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Sahnghai, China

Genomic Study of Relapse Esophageal Cancer After Radiotherapy

Conditions: Radiation Exposure
Gene Mutation-Related Cancer
Esophageal Cancer

Interventions: Genetic: whole exome sequence

First Posted Date: 2021-01-05

Last Posted Date: 2021-01-26

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04694391

Locations: 🇨🇳
Fudan university shanghai cancer center, Shanghai, China

Prepectoral and Subpectoral Implant-based Breast Reconstruction

Not Applicable

Conditions: Breast Carcinoma
Breast Reconstruction

Interventions: Procedure: subpectoral implant-based reconstruction
Procedure: prepectoral implant-based reconstruction

First Posted Date: 2020-12-30

Last Posted Date: 2020-12-30

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT04688697

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Phase 3

Recruiting

Conditions: Liver Metastases
Colorectal Cancer

Interventions: Drug: mFOLFOXIRI plus Cetuximab
Drug: mFOLFOXIRI Plus Bevacizumab

First Posted Date: 2020-12-29

Last Posted Date: 2024-12-18

Lead Sponsor: Fudan University

Target Recruit Count: 508

Registration Number: NCT04687631

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis

Phase 2

Conditions: Pancreatic Cancer Metastatic to Liver
Oligometastasis

Interventions: Combination Product: Microwave Ablation combination with chemotherapy

First Posted Date: 2020-12-21

Last Posted Date: 2020-12-21

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT04677192

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Diagnostic Accuracy of CCTA-derived Versus AngiogRaphy-dErived QuantitativE Flow Ratio (CAREER) Study

Conditions: Coronary Artery Disease
Hemodynamics
Coronary Computed Tomography Angiography
Coronary Stenosis

First Posted Date: 2020-12-14

Last Posted Date: 2022-01-25

Lead Sponsor: Fudan University

Target Recruit Count: 216

Registration Number: NCT04665817

Locations: 🇨🇳
Xinkai Qu, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy